# US 8,784,814 B2 · Method for inhibiting binding to B-cell receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,814 B2
- Document ID: US8784814B2
- Status: Granted
- Kind: B2
- Application number: 13/536,028
- Filed: 2012-06-28
- Published: 2014-02-27
- Granted: 2014-07-22
- Earliest claimed: 2007-05-08
- Assignees: Glaxo Group Limited
- Applicants: Stuart Neville Farrow; Allard Kaptein; Jeremy David Alistair Kitson; Alison J. Winder
- Inventors: Stuart Neville Farrow; Allard Kaptein; Jeremy David Alistair Kitson; Alison J. Winder
- Web page: https://patentgrep.com/patent/US8784814B2

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprises: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).

## Claims

### Claim 1

A method of inhibiting the interaction in a mammal between a receptor on B-cells and a homotrimeric polypeptide comprising a first polypeptide having 99% sequence identity to SEQ ID NO: 1, said method comprising administering to said mammal an antibody or a fragment thereof that specifically binds a second polypeptide consisting of SEQ ID NO:2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody or fragment thereof binds to the extracellular domain of said second polypeptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antibody is a monoclonal antibody.

### Claim 5

A method of inhibiting the binding of a receptor on B-cells with a homotrimeric polypeptide comprising a first polypeptide having 99% sequence identity to SEQ ID NO: 1, said method comprising contacting said homotrimeric polypeptide with an antibody or fragment thereof that specifically binds a second polypeptide consisting of SEQ ID NO:2.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody or fragment thereof binds to the extracellular domain of said second polypeptide.

### Claim 7 (depends on 5)

The method of claim 5, wherein said antibody is a monoclonal antibody.